Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors

Inclusion Criteria: * History of biopsy proven neuroendocrine tumor including (but not limited to): gastrointestinal NET, pancreatic NET, pulmonary NET, NET unknown primary, pheochromocytoma, paraganglioma, medullary thyroid cancer, medulloblastoma, meningioma * At least two abnormal 68Ga-HA-DOTATATE positive lesions suspected to represent neuroendocrine tumor (at least tow lesions with SUVmax \> SUV meanliver). * Age greater or equal to 40 * Ability to provide written informed consent prior to participation in the study Exclusion Criteria: * Weight \> 225 kg (weight limitation of PET/CT scanner) * Inability to scan (ie. extreme claustrophobia) or inability to lie still for imaging * Any medical condition, serious inter-current illness, or other extenuating circumstance that, in the opinion of the investigator or attending department physician, may significantly interfere with study performance or interpretation * Previous allergic reaction to 18F-DOPA * Lack of intravenous access * Pregnant * Breastfeeding * Less than 40 years old